Chloroquine - NDSRI's
References
FAQ's
References
- Andersag, Hans; Breitner, Stefan; Jung, Heinrich, Quinoline Compound And Process Of Making The Same, Winthrop Chemical Co., US2233970A, March 4, 1941
- Bergqvist, Yngve; Frisk-Holmberg, Marianne, Sensitive method for the determination of chloroquine and its metabolite desethylchloroquine in human plasma and urine by high-performance liquid chromatography, Journal of Chromatography, Biomedical Applications, Volume: 221, Issue: 1, Pages: 119-27, 1980
Frequently Asked Questions
What is the impact of impurities on Chloroquine?
Impurities in Chloroquine can affect the drug's safety, efficacy, and stability. Some may be toxic or cause harm, while others may reduce the drug's potency or shelf-life.
How can the level of Chloroquine impurities be quantified?
The level of impurities in Chloroquine can be quantified using validated analytical methods, such as HPLC or LC-MS. Their amount is reported as a percentage of the drug substance.
How can Chloroquine impurities be minimized during manufacturing?
Chloroquine impurities may minimize during manufacturing by using high-quality raw materials, implementing GMPs, and using validated purification processes. Additionally, regular monitoring and testing can help to detect and control impurities.
What are the temperature conditions required to store Chloroquine impurities?
Chloroquine impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.